Company intelligence / Profile preview

Norroy Bioscience Co., Ltd.

Wuxi, Jiangsu Province, Chinacrunchbase.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

The company has received clinical trial approvals for several radiopharmaceutical drugs including 177Lu-NY108(NYM032) for prostate cancer and 68Ga-NY104(NYM005) for renal cancer in both China and the US. Their 18F-NY104 diagnostic nuclear drug has entered Phase 0 clinical trials.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalsNuclear medicine
Industry: Biotech

Drug pipeline

2 assets

89Zr-NY005

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Norroy Bioscience Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norroy Bioscience Co., Ltd..

Explore the full profile